The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
BUSINESS
Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
Combined sales of 11 major non-Japanese drug makers in Japan slipped 1.8% in 2014 compared to the previous year, resulting in lower profits, according to a Jiho tally. The decline, chiefly blamed on the NHI drug price revision implemented in…
To read the full story
Related Article
- AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
May 27, 2022
- Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
- Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
- Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
- AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
- Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
- 2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
June 2, 2014
- Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
May 23, 2014
BUSINESS
- Kissei Cuts H1 Profit Outlook on Tavneos Approval Revocation Risk
October 29, 2026
- Nxera Licenses Fabry Disease Drug from Idorsia
October 29, 2026
- Novo Nordisk Hints at GLP-1 Supply Restrictions to Curb Inappropriate Use
October 29, 2026
- J-TEC, Maruho to Co-Promote Jacemin from April
October 29, 2026
- KM Biologics to Supply Mpox Vaccine to WHO-Led Vaccine Stockpile
October 29, 2026
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…